Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73. An interim readout from the...

DISEASE CATEGORY: Endocrine/metabolic; musculoskeletal INDICATION: Obesity; musculoskeletal Promoting adenosine signaling through ADORA2B could treat obesity and aging-induced sarcopenia. In brown adipose tissue biopsies from lean and overweight individuals, ADORA2B expression was lower in older individuals...

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...

Gilead’s tie-up with Pionyr marks the big biotech’s fifth cancer deal this year and gives it access to mAbs against immunosuppressive tumor myeloid cells. In an agreement announced Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) will pay...

iTeos Therapeutics S.A. made several hires Tuesday, including Matthew Gall as CFO and Yvonne McGrath as VP of R&D. Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix...

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...

Shares of oncology company Arcus rose sharply Thursday as the company remained quiet about a published report that said Gilead had approached it about a partnership or equity investment. Arcus Biosciences Inc. (NYSE:RCUS) gained $14.01...